CN111110859A - Maytansine polypeptide conjugate and preparation method and application thereof - Google Patents
Maytansine polypeptide conjugate and preparation method and application thereof Download PDFInfo
- Publication number
- CN111110859A CN111110859A CN201811282316.9A CN201811282316A CN111110859A CN 111110859 A CN111110859 A CN 111110859A CN 201811282316 A CN201811282316 A CN 201811282316A CN 111110859 A CN111110859 A CN 111110859A
- Authority
- CN
- China
- Prior art keywords
- maytansine
- polypeptide
- aaa
- conjugate
- synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 54
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 51
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 51
- 229930126263 Maytansine Natural products 0.000 title claims abstract description 33
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 9
- 239000007791 liquid phase Substances 0.000 claims description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000007790 solid phase Substances 0.000 claims description 5
- 238000001308 synthesis method Methods 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 238000005336 cracking Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims description 3
- 230000001376 precipitating effect Effects 0.000 claims description 3
- MEZJQXVOMGUAMP-UHFFFAOYSA-N 1-(2-methylnaphthalen-1-yl)pyrrole-2,5-dione Chemical compound CC1=CC=C2C=CC=CC2=C1N1C(=O)C=CC1=O MEZJQXVOMGUAMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 27
- 229940079593 drug Drugs 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 12
- 210000004027 cell Anatomy 0.000 abstract description 10
- 210000004899 c-terminal region Anatomy 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 239000004475 Arginine Substances 0.000 abstract description 3
- 239000004472 Lysine Substances 0.000 abstract description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract description 3
- 239000012528 membrane Substances 0.000 abstract description 3
- 230000000149 penetrating effect Effects 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- SLXXEMSPHFYCLE-UHFFFAOYSA-N ethane-1,1-dithiol;hydrate Chemical compound O.CC(S)S SLXXEMSPHFYCLE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a maytansine polypeptide conjugate, a preparation method and application thereof, and the maytansine polypeptide conjugate has a molecular structure shown as a formula I:
wherein Aaa1Lys or Arg in L or D form; aaa2Any natural amino acid in L or D form; aaa3Any natural amino acid in L or D form; aaa4Lys or Arg in L or D form; r1Is cyclohexyl or- (CH)2)n-, n is 1 to 10; r2-SH is beautyDentin DM1 or DM 4. The maytansine polypeptide conjugate provided by the invention can realize targeted drug delivery, and simultaneously, a sequence conforming to the C-terminal rule (Cend R) -R/KXXR/K (R: arginine, K: lysine and X: any amino acid) is introduced into the C terminal to increase the membrane penetrating capacity of the drug to tumor cells, so that the drug can rapidly enter the cells, the drug curative effect is increased, and the toxic and side effects to normal cells are reduced.
Description
Technical Field
The invention relates to a maytansine polypeptide conjugate and a preparation method and application thereof, in particular to a maytansine polypeptide conjugate applied to tumor targeted therapy and a preparation method and application thereof.
Background
Maytansine (Maytansine) is a drug with high cytotoxicity, is firstly separated from east African shrub Maytansine by Kupchan and the like, and according to related research reports, the toxicity of Maytansine is 100 to 1000 times stronger than that of traditional antitumor drugs such as methotrexate, paclitaxel, camptothecin and the like, but the clinical application of the Maytansine drug is limited mainly due to the strong toxic and side effects on central nervous system and gastrointestinal symptoms.
The small molecular targeted peptide can selectively target the drug to a tumor part through receptor interaction, so that the therapeutic drug is concentrated in a focal region, the drug concentration of the focal region is several times or even hundreds times higher than that of a conventional preparation, the efficiency of systemic chemotherapy is improved, and the toxic and side effects of the drug are greatly reduced, for example, LTVSPWWY polypeptide can be specifically combined with a Her2 receptor on the surface of a tumor cell. However, the traditional targeting peptide can only carry a drug to tumor cells, and the drug can not enter the cells because the physicochemical property characteristics of the targeting peptide are difficult to cross cell membranes, and researches show that the polypeptide with a C-terminal sequence of R/KXXR/K (R: arginine, K: lysine, X: any amino acid) has the function of tissue penetration, namely C-terminal rule (Cend R).
Disclosure of Invention
The invention provides a maytansine polypeptide conjugate and a preparation method and application thereof, aiming at the defects of poor selectivity, poor water solubility, insufficient membrane penetrating capability of target polypeptide and the like of the existing maytansine drugs.
The technical scheme for solving the technical problems is as follows:
a maytansine polypeptide conjugate having the molecular structural formula shown in formula i:
wherein Aaa1Lys or Arg in L or D form; aaa2Any natural amino acid in L or D form; aaa3Any natural amino acid in L or D form; aaa4Lys or Arg in L or D form; r1Is cyclohexyl or- (CH)2)n-, n is 1 to 10; r2-SH is maytansine DM1 or DM 4.
Further, the maytansine polypeptide conjugate is preferably Aaa1Is L-type Arg, Aaa2Is L-type Gly, Aaa3Is L-type Asp, Aaa4Is L-type Arg and has a structural formula shown as a formula II:
wherein R is1Is cyclohexyl or- (CH)2)n-, n is 1 to 10; r2-SH is maytansine DM1 or DM 4.
The maytansine polypeptide conjugate provided by the invention has the beneficial effects that:
1) the maytansine is coupled with the polypeptide, so that targeted drug delivery can be realized, the targeted polypeptide conveys the maytansine to specific tumor cells, the targeting property of the maytansine is improved, the curative effect of the drug is improved, and the toxic and side effects of the maytansine on normal cells are reduced;
2) the conjugate provided by the invention is characterized in that a C-terminal is introduced into a C-terminal, wherein the C-terminal accords with the C-terminal rule (Cend R) -R/KXXR/K (R: arginine; k is lysine; x is any amino acid), the membrane penetrating capacity of the medicament on tumor cells is increased, and the anti-tumor curative effect of the medicament is further increased.
The invention also claims a preparation method of the maytansine polypeptide conjugate, which comprises the following steps:
(1) synthesis of polypeptide fragments:
synthesizing amino acid sequences in sequence by using a solid-phase polypeptide synthesis method adopting an Fmoc strategy to obtain polypeptide fragments;
(2) synthesis of Linker-LTVSPWYRGDR:
taking 4- (N-maleimide methyl) cyclohexyl formic acid or N-maleimide straight-chain carboxylic acid as a raw material, directly connecting the raw material with the polypeptide fragment obtained in the step (1) by a solid-phase synthesis method, cracking after the synthesis is finished, precipitating by ether, purifying a prepared liquid phase, and freeze-drying to obtain Linker-LTVSPWYRGDR;
(3) synthesis of maytansine-LTVSPWYRGDR conjugate:
and (3) mixing maytansine DM1 or DM4 with the Linker-LTVSPWYRGDR prepared in the step (2) according to a molar ratio (1-3): dissolving the product 1 in an organic solvent, adding a PBS buffer solution to adjust the pH value to 6-8, stirring and reacting for 1-6 hours at room temperature to obtain a reaction solution, directly performing preparative liquid phase purification on the reaction solution, combining fractions containing the product, concentrating and freeze-drying to obtain the maytansine-LTVSPWYRGDR conjugate.
The invention also claims the application of the maytansine polypeptide conjugate in the field of antitumor drugs.
Further, the tumor is gastric cancer.
Drawings
FIG. 1 is an ESI-MS diagram of a DM1 polypeptide conjugate obtained in example 1;
FIG. 2 is a comparison of the proliferation inhibitory activity of DM1 polypeptide-conjugated drug obtained in example 1 against the proliferation inhibitory activity of DM1 against gastric cancer cell N87.
Detailed Description
The principles and features of this invention are described below in conjunction with examples, which are set forth to illustrate, but are not to be construed to limit the scope of the invention.
Example 1:
a maytansine polypeptide conjugate having the formula:
the synthesis of the targeting polypeptide of the present invention was carried out using a solid phase polypeptide synthesis method using Fmoc strategy using a polypeptide synthesizer manufactured by CSBio Inc.
Selection of reagents used in synthesis:
(1) carrier resin: Fmoc-Arg (Pbf) Wang, degree of substitution: 0.67
(2) Selected protected amino acids: Fmoc-Leu-OH, Fmoc-Thr (tBu) -OH, Fmoc-Val-OH, Fmoc-Ser (tBu) -OH, Fmoc-Pro-OH, Fmoc-Trp (Boc) -OH, Fmoc-Tyr (tBu) -OH, Fmoc-Arg (pbf) -OH, Fmoc-Gly-OH, Fmoc-Asp (OtBu) -OH, N-maleimidocaproic acid, 3-fold excess of protected amino acids used in the reaction.
(3) The deprotection reagent used in the invention is: piperidine/N, N-dimethylformamide in a ratio of 20: 80.
(4) The coupling reagents used in the present invention are: DIEA/HBTU.
(5) The cleavage reagents used in the present invention were: TFA/triisopropylsilane/water/1, 2-ethanedithiol in the following ratios: 94:2:2:2. Precipitating with 10 times volume of ether, purifying the obtained crude polypeptide with C18 preparative column, detecting wavelength: 214nm, mobile phase a: acetonitrile (containing 0.1% trifluoroacetic acid), mobile phase B: water (containing 0.1% trifluoroacetic acid). MS determines the molecular weight of the obtained pure product, HPLC determines the purity of the sample, and freeze-drying is carried out to obtain the target polypeptide.
The preparation method of the polypeptide drug conjugate comprises the following steps:
1) synthesis of MH-LTVSPWYRGDR:
the solid-phase polypeptide synthesis method using Fmoc strategy is used for sequentially carrying out amino acid sequence synthesis to obtain polypeptide fragments, and then directly connecting the polypeptide fragments with N-maleimidocaproic acid through solid-phase synthesis to obtain MH-LTVSPWYRGDR. Starting reaction with 0.2g of Fmoc-Arg (Pbf) Wang resin, cracking to obtain 140mg of crude polypeptide, and purifying with preparative liquid phase to obtain 52mg of crude polypeptide with a total yield of 25%.
2) Synthesis of DM 1-MH-LTVSPWYRGDR:
DM1(18mg, 0.025mmol, 1.25eq) and MH-LTVSPWYRGDR (30mg, 0.02mmol) were dissolved in 1mL THF, 1mL PBS buffer was added to adjust the pH to 6-8, the reaction was stirred at room temperature, and HPLC showed completion for about 3 hours. The reaction was directly purified from the preparative liquid phase, the fractions containing the product were combined, concentrated and lyophilized to give 18mg of solid in 39% yield.
MS tests show that DM1-MH-LTVSPWYRGDR conjugate (DM1 polypeptide conjugated drug) is obtained.
The synthetic route is as follows:
example 2:
a maytansine polypeptide conjugate having the formula:
the preparation method of the polypeptide drug conjugate precursor comprises the following steps:
1) synthesis of MCC-LTVSPWYRGDR:
the amino acid sequence synthesis is carried out sequentially by using a solid-phase polypeptide synthesis method of Fmoc strategy, and the 4- (N-maleimidomethyl) cyclohexyl formic acid is directly connected with a polypeptide fragment through solid-phase synthesis to obtain the MCC-LTVSPWYRGDR. Starting reaction with 0.2g of Fmoc-Arg (Pbf) Wang resin, cracking to obtain 120mg of crude polypeptide, and purifying with preparative liquid phase to obtain 44mg of crude polypeptide with 21% of total yield.
2) Synthesis of DM 4-MCC-LTVSPWYRGDR:
DM4(50mg, 0.06mmol, 3eq), MCC-LTVSPWYRGDR (31mg, 0.02mmol) are dissolved in 1mL THF, 1mL PBS buffer is added to adjust the pH value of the system to 6-8, then the reaction is stirred at room temperature, and HPLC shows that the reaction is completed for about 3 hours. The reaction was directly purified from the preparative liquid phase, the fractions containing the product were combined, concentrated and lyophilized to give 12mg of a solid in 26% yield.
MS test shows that DM4-MCC-LTVSPWYRGDR conjugate is obtained.
The synthetic route is as follows:
in order to verify the proliferation inhibition effect of the polypeptide drug conjugate on tumor cells, we performed an in vitro anti-tumor cell effect comparison experiment on the DM1 polypeptide conjugate drug obtained in example 1 and DM1, and we performed the proliferation inhibition effect experiment on the DM1 polypeptide conjugate drug obtained in example 1 and DM1 respectively by taking the gastric cancer cell N87 as an example, and the specific operation process was as follows:
taking cells in logarithmic growth phase, adjusting appropriate cell density, inoculating into 96-well plate, culturing at 37 deg.C and 5% CO in 100 μ l/well2In the incubator. After overnight culture, the drug was administered for 48 h. A blank group and an administration group are respectively arranged, and each group is provided with 4 multiple holes. The in vitro anti-gastric cancer effect is shown in fig. 2. As can be seen from FIG. 2, the DM1 polypeptide-conjugated drug has approximate cytotoxicity to DM1, and the DM1 polypeptide-conjugated drug has half lethal dose IC of gastric cancer cell N87500.610 μ M, has strong antitumor activity.
In conclusion, the polypeptide drug conjugate provided by the invention has good water solubility, and experiments prove that the polypeptide drug conjugate has basically the same anti-tumor activity as the original drug and can exert the inhibition effect on tumor cells within 48 hours.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (5)
1. A maytansine polypeptide conjugate having the molecular structure of formula i:
wherein Aaa1Lys or Arg in L or D form; aaa2Any natural amino acid in L or D form; aaa3Any natural amino acid in L or D form; aaa4Lys or Arg in L or D form; r1Is cyclohexyl or- (CH)2)n-, n is 1 to 10; r2-SH is maytansine DM1 or DM 4.
2. The maytansinoid polypeptide conjugate of claim 1, having a molecular structure according to formula ii:
wherein R is1Is cyclohexyl or- (CH)2)n-, n is 1 to 10; r2-SH is maytansine DM1 or DM 4.
3. The method of producing a maytansine polypeptide conjugate of claim 1 or 2, comprising the steps of:
(1) synthesis of polypeptide fragments:
synthesizing amino acid sequences in sequence by using a solid-phase polypeptide synthesis method adopting an Fmoc strategy to obtain polypeptide fragments;
(2) synthesis of Linker-LTVSPWYRGDR:
taking 4- (N-maleimide methyl) cyclohexyl formic acid or N-maleimide straight-chain carboxylic acid as a raw material, directly connecting the raw material with the polypeptide fragment obtained in the step (1) by a solid-phase synthesis method, cracking after the synthesis is finished, precipitating by ether, purifying a prepared liquid phase, and freeze-drying to obtain Linker-LTVSPWYRGDR;
(3) synthesis of maytansine-LTVSPWYRGDR conjugate:
and (3) mixing maytansine DM1 or DM4 with the Linker-LTVSPWYRGDR prepared in the step (2) according to a molar ratio (1-3): dissolving the product 1 in an organic solvent, adding a PBS buffer solution to adjust the pH value to 6-8, stirring and reacting for 1-6 hours at room temperature to obtain a reaction solution, directly performing preparative liquid phase purification on the reaction solution, combining fractions containing the product, concentrating and freeze-drying to obtain the maytansine-LTVSPWYRGDR conjugate.
4. The maytansinoid polypeptide conjugate of claim 1 or 2, for use in the field of anti-tumor drugs.
5. The use of claim 4, wherein the tumor is gastric cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811282316.9A CN111110859A (en) | 2018-10-31 | 2018-10-31 | Maytansine polypeptide conjugate and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811282316.9A CN111110859A (en) | 2018-10-31 | 2018-10-31 | Maytansine polypeptide conjugate and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111110859A true CN111110859A (en) | 2020-05-08 |
Family
ID=70484947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811282316.9A Pending CN111110859A (en) | 2018-10-31 | 2018-10-31 | Maytansine polypeptide conjugate and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111110859A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107335060A (en) * | 2016-04-28 | 2017-11-10 | 北京大学 | A kind of small molecule conjugate and its nano prodrug system based on rgd peptide-chemotherapeutics |
| CN107952080A (en) * | 2016-10-14 | 2018-04-24 | 中国科学院过程工程研究所 | A kind of cancer target polypeptide-drug coupling derivative, its preparation method and application |
| CN108187065A (en) * | 2017-12-29 | 2018-06-22 | 广东众生药业股份有限公司 | Anti- 5T4 antibody and maytansine derivative DM4 coupled complexes and preparation method and purposes |
-
2018
- 2018-10-31 CN CN201811282316.9A patent/CN111110859A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107335060A (en) * | 2016-04-28 | 2017-11-10 | 北京大学 | A kind of small molecule conjugate and its nano prodrug system based on rgd peptide-chemotherapeutics |
| CN107952080A (en) * | 2016-10-14 | 2018-04-24 | 中国科学院过程工程研究所 | A kind of cancer target polypeptide-drug coupling derivative, its preparation method and application |
| CN108187065A (en) * | 2017-12-29 | 2018-06-22 | 广东众生药业股份有限公司 | Anti- 5T4 antibody and maytansine derivative DM4 coupled complexes and preparation method and purposes |
Non-Patent Citations (1)
| Title |
|---|
| 李莉: "新型药物递送系统 LTV-HR与酸敏感性穿膜肽LH-1、LH-2 的设计、合成以及活性测定", 《中国优秀博硕士学位论文全文数据库（硕士） 医药卫生辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60026300T2 (en) | PROTECTION OF ENDOGENOUS, THERAPEUTICALLY ACTIVE PEPTIDES FROM PEPTIDASE ACTIVITY BY CONJUGATION TO BLOOD COMPONENTS | |
| CN110003055B (en) | Amino diacids containing peptide modifiers | |
| US11718654B2 (en) | IL-2R-βγ binding compounds | |
| CN112386707B (en) | Tumor targeting polypeptide drug conjugate and preparation method thereof | |
| EP4055036A1 (en) | Dual il-2r and il-7r binding compounds | |
| AU2020214507A1 (en) | Bi-ligand drug conjugate and use thereof | |
| EP3020724A1 (en) | Cell-penetrating peptide and conjugate comprising same | |
| CN111574592B (en) | Cyclic peptide compounds with antagonistic PD-1/PD-L1 interaction and application thereof | |
| CN115192730A (en) | Bispecific polypeptide nano-drug targeting PD-L1 and preparation method and application thereof | |
| US20200247842A1 (en) | Immune-stimulating soluble doxorubicin-conjugated complex | |
| CN111040020A (en) | Alkene thioether staple peptide and preparation method and application thereof | |
| KR20080033120A (en) | A method for preparing peptides using by solid phase synthesis | |
| EP0353565B1 (en) | Immunostimulating peptides, a process for their preparation and pharmaceutical commpositions containing them | |
| CN111110858A (en) | Her2 targeted polypeptide drug conjugate as well as preparation method and application thereof | |
| KR20180124412A (en) | Conjugate of methotrexate and peptide | |
| CN111110859A (en) | Maytansine polypeptide conjugate and preparation method and application thereof | |
| CN109908363B (en) | Targeted traceless release drug conjugate and preparation method and application thereof | |
| CN111110860A (en) | Reduction response type Her2 targeted polypeptide drug conjugate and preparation method and application thereof | |
| JP2013087098A (en) | Cell membrane permeable boron peptide | |
| CN110724179B (en) | Anti-tumor polypeptide and preparation method and application thereof | |
| CN117003819A (en) | Tumor receptor targeted maytansine polypeptide conjugate and preparation method and application thereof | |
| CN117106035B (en) | Tumor targeting polypeptide, polypeptide coupling drug, preparation and application | |
| CN115925813B (en) | Membrane penetrating cyclic peptide and preparation method and application thereof | |
| CN114515339B (en) | Polypeptide coupling medicine for somatostatin receptor and application thereof | |
| US20230357342A1 (en) | Modified il-18 polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200508 |
|
| RJ01 | Rejection of invention patent application after publication |